Spatial biology is the next life science revolution
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
List view / Grid view
Dr Richard Goodwin, Head of Imaging & AI, Clinical Pharmacology & Safety Sciences at AstraZeneca, explores the latest innovation in early therapeutic development – spatial biology.
Researchers have developed a ground-breaking microscopy technique that allows proteins, DNA, and other tiny biological particles to be studied in their natural state in a completely new way.
Scientists have identified an important new mechanism that causes the heart’s muscle to thicken which markedly increases the risk of irregular heart rhythms and cardiac hypertrophy.
Researchers have developed a new bioinformatics pipeline that could help investigate the mechanism underlying the development of autoimmune diseases following SARS-CoV-2 infection.
Scientists have developed a novel type 1 diabetes treatment that involves transplanting pancreas cells that produce insulin.
A new study from Niigata University has found a binding protein that is vital for proper development of the central nervous system.
Long-awaited findings about cell differentiation will be relevant in understanding normal development and may also be useful in cancer research.
A molecular cage, developed for use during cryo-EM, has provided researchers with new insights into a key cancer protein.
During investigations into the tropical disease Buruli ulcer, researchers have instead identified a promising new avenue for potential treatments for multiple myeloma.
The capability to edit genes has been transformative in opening therapeutic avenues for hitherto untreatable diseases and aiding biological insight. Scientists have now discovered a way to enhance this process using retrons, making the process more efficient and effective.
The new study identified PDZ-binding kinase (PBK) as a promising target for pulmonary hypertension and assessed two PBK inhibitors.
A microplate-based method for the determination of association and dissociation rate values in high throughput using a kinetic probe competition assay (kPCA).
Gallic acid was found to decrease arthritis inflammation markers and improve the production of desired proteins in arthritic knee cells.
The study reveals the biological mechanism that causes nerve destruction in amyotrophic lateral sclerosis (ALS), potentially leading to treatments that reverse the disease.
Infusions of purified IL-27 regulatory B cells (I27-Bregs) reduced symptoms in mouse models of multiple sclerosis and autoimmune uveitis.